O	0	8	Avoiding
O	9	17	axillary
O	18	28	dissection
O	29	31	in
O	32	38	breast
O	39	45	cancer
O	46	53	surgery
O	53	54	:
O	55	56	a
O	57	67	randomized
O	68	73	trial
O	74	76	to
O	77	83	assess
O	84	87	the
O	88	92	role
O	93	95	of
B-intervention	96	104	axillary
I-intervention	105	117	radiotherapy
O	117	118	.

O	119	122	The
O	123	127	need
O	128	130	to
O	131	138	dissect
O	139	147	axillary
O	148	153	nodes
O	154	156	in
O	157	165	patients
O	166	170	with
O	171	176	early
O	177	183	breast
O	184	190	cancer
O	191	194	and
O	195	205	clinically
O	206	214	negative
O	215	221	axilla
O	222	229	remains
O	230	243	controversial
O	243	244	.

O	245	248	The
O	249	252	aim
O	253	255	of
O	256	259	the
O	260	265	study
O	266	269	was
O	270	272	to
O	273	279	assess
O	280	283	the
O	284	288	role
O	289	291	of
O	292	300	axillary
O	301	313	radiotherapy
O	314	315	(
O	315	317	RT
O	317	318	)
O	319	321	in
O	322	330	reducing
O	331	339	axillary
O	340	350	metastases
O	351	353	in
B-eligibility	354	362	patients
I-eligibility	363	367	with
I-eligibility	368	373	early
I-eligibility	374	380	breast
I-eligibility	381	387	cancer
I-eligibility	388	391	who
I-eligibility	392	395	did
I-eligibility	396	399	not
I-eligibility	400	407	receive
I-eligibility	408	416	axillary
I-eligibility	417	427	dissection
O	427	428	.

O	429	433	From
O	434	438	1995
O	439	441	to
O	442	446	1998
O	446	447	,
B-total-participants	448	451	435
O	452	460	patients
B-age	461	465	over
I-age	466	468	45
I-age	469	474	years
O	475	478	old
O	479	483	with
O	484	490	breast
O	491	497	cancer
O	498	500	up
O	501	503	to
O	504	505	1
O	505	506	.
O	506	507	2
O	508	510	cm
O	511	514	and
O	515	517	no
O	518	526	palpable
O	527	535	axillary
O	536	541	nodes
O	542	546	were
O	547	557	randomized
B-control-participants	558	561	214
O	562	564	to
B-control	565	571	breast
I-control	572	584	conservation
I-control	585	592	without
I-control	593	601	axillary
I-control	602	611	treatment
O	612	615	and
B-intervention-participants	616	619	221
O	620	622	to
O	623	629	breast
O	630	642	conservation
O	643	647	plus
O	648	656	axillary
O	657	659	RT
O	659	660	.

O	661	666	After
O	667	668	a
O	669	675	median
O	676	682	follow
O	682	683	-
O	683	685	up
O	686	688	of
O	689	691	63
O	692	698	months
O	698	699	,
B-outcome	700	705	overt
I-outcome	706	714	axillary
I-outcome	715	725	metastases
O	726	730	were
O	731	736	fewer
O	737	741	than
O	742	750	expected
O	750	751	:
B-cv-bin-abs	752	757	three
O	758	763	cases
O	764	766	in
O	767	770	the
O	771	773	no
O	774	782	axillary
O	783	792	treatment
O	793	798	group
O	799	800	(
B-cv-bin-percent	800	801	1
I-cv-bin-percent	801	802	.
I-cv-bin-percent	802	803	5
I-cv-bin-percent	803	804	%
O	804	805	)
O	806	809	and
B-iv-bin-abs	810	813	one
O	814	816	in
O	817	820	the
O	821	823	RT
O	824	829	group
O	830	831	(
B-iv-bin-percent	831	832	0
I-iv-bin-percent	832	833	.
I-iv-bin-percent	833	834	5
I-iv-bin-percent	834	835	%
O	835	836	)
O	836	837	.

B-outcome	838	846	Expected
I-outcome	847	852	cases
O	853	857	were
B-cv-bin-abs	858	860	43
O	861	863	in
O	864	867	the
O	868	870	no
O	871	879	axillary
O	880	889	treatment
O	890	895	group
O	896	899	and
B-iv-bin-abs	900	902	10
O	903	905	in
O	906	909	the
O	910	912	RT
O	913	918	group
O	918	919	.

B-outcome	920	925	Rates
I-outcome	926	928	of
I-outcome	929	936	distant
I-outcome	937	947	metastases
O	948	951	and
B-outcome	952	957	local
I-outcome	958	966	failures
O	967	971	were
O	972	975	low
O	975	976	,
O	977	980	and
B-outcome	981	982	5
I-outcome	982	983	-
I-outcome	983	987	year
I-outcome	988	995	disease
I-outcome	996	1000	free
I-outcome	1001	1009	survival
O	1010	1013	was
O	1014	1016	96
O	1016	1017	.
O	1017	1018	0
O	1018	1019	%
O	1020	1021	(
O	1021	1023	95
O	1023	1024	%
O	1025	1035	confidence
O	1036	1044	interval
O	1044	1045	,
O	1046	1048	94
O	1048	1049	.
O	1049	1050	1
O	1050	1051	%
O	1051	1052	-
O	1052	1054	97
O	1054	1055	.
O	1055	1056	9
O	1056	1057	%
O	1057	1058	)
O	1059	1066	without
O	1067	1078	significant
O	1079	1090	differences
O	1091	1098	between
O	1099	1102	the
O	1103	1106	two
O	1107	1111	arms
O	1111	1112	.

O	1113	1117	This
O	1118	1123	study
O	1124	1132	suggests
O	1133	1137	that
O	1138	1144	occult
O	1145	1153	axillary
O	1154	1164	metastases
O	1165	1170	might
O	1171	1176	never
O	1177	1183	become
O	1184	1194	clinically
O	1195	1200	overt
O	1201	1204	and
O	1205	1213	axillary
O	1214	1224	dissection
O	1225	1230	might
O	1231	1233	be
O	1234	1241	avoided
O	1242	1244	in
O	1245	1253	patients
O	1254	1258	with
O	1259	1264	small
O	1265	1275	carcinomas
O	1276	1279	and
O	1280	1281	a
O	1282	1292	clinically
O	1293	1301	negative
O	1302	1308	axilla
O	1308	1309	.

O	1310	1318	Axillary
O	1319	1321	RT
O	1322	1327	seems
O	1328	1330	to
O	1331	1338	protect
O	1339	1342	the
O	1343	1351	patients
O	1352	1356	from
O	1357	1365	axillary
O	1366	1376	recurrence
O	1377	1383	almost
O	1384	1394	completely
O	1394	1395	.
